儿童胃肠炎多剂量口服昂丹司琼的实用随机对照试验(DOSE-AGE研究):统计分析计划
DOSE-AGE是一项III期、6中心、安慰剂对照、双盲、平行设计随机对照试验,旨在评估急诊离院后按需多剂量口服昂丹司琼能否降低儿童急性胃肠炎相关呕吐的中重度发生率(以改良Vesikari量表评分衡量)。本文预先提交统计分析计划(SAP),以减少数据驱动结果和报告偏倚。
要点
- 多剂量昂丹司琼组与安慰剂组比较改良Vesikari量表评分的中重度胃肠炎发生率。
- 安全性评估包括腹泻发作频率和最大次数、心悸、晕厥前/晕厥、胸痛、心律失常及严重不良事件。
- 次要结局包括改良Vesikari量表各成分及照护者治疗满意度。
核心结论
- DOSE-AGE试验将提供证据评估急诊初始剂量后按需多剂量口服昂丹司琼治疗儿童急性胃肠炎相关呕吐的有效性。
- 使用预先制定的SAP分析数据可降低数据驱动结果和报告偏倚的风险。
研究设计与样本
- III期、6中心、安慰剂对照、双盲、平行设计随机对照试验。
- 研究对象为急诊就诊的急性胃肠炎伴呕吐儿童,急诊离院后按需给予多剂量口服昂丹司琼或安慰剂。
- 试验注册于ClinicalTrials.gov(NCT03851835),注册日期2019年2月22日。
关键数值与推荐
- 主要结局为改良Vesikari量表评分定义的中重度胃肠炎发生率。
- 安全性结局包括腹泻发作频率和最大次数、心悸、晕厥前/晕厥、胸痛、心律失常及严重不良事件。
- 次要结局包括改良Vesikari量表各成分及照护者治疗满意度。
临床怎么用
- 该SAP为DOSE-AGE试验的结果分析提供预先规定的方法,支持后续临床决策证据的产生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute gastroenteritis is a leading cause of emergency department visits and hospitalizations among children in North America. Oral-rehydration therapy is recommended for children with mild-to-moderate dehydration, but children who present with vomiting are frequently offered intravenous rehydration in the emergency department (ED). Recent studies have demonstrated that the anti-emetic ondansetron can reduce vomiting, intravenous rehydration, and hospitalization when administered in the ED to children with dehydration. However, there is little evidence of additional benefit from prescribing ondansetron beyond the initial ED dose. Moreover, repeat dosing may increase the frequency of diarrhea. Despite the lack of evidence and potential adverse side effects, many physicians across North America provide multiple doses of ondansetron to be taken following ED disposition. Thus, the Multi-Dose Oral Ondansetron for Pediatric Gastroenteritis (DOSE-AGE) trial will evaluate the effectiveness of prescribing multiple doses of ondansetron to treat acute gastroenteritis-associated vomiting. This article specifies the statistical analysis plan (SAP) for the DOSE-AGE trial and was submitted before the outcomes of the study were available for analysis. METHODS/DESIGN: The DOSE-AGE study is a phase III, 6-center, placebo-controlled, double-blind, parallel design randomized controlled trial designed to determine whether participants who are prescribed multiple doses of oral ondansetron to administer, as needed, following their ED visit have a lower incidence of experiencing moderate-to-severe gastroenteritis, as measured by the Modified Vesikari Scale score, compared with a placebo. To assess safety, the DOSE-AGE trial will investigate the frequency and maximum number of diarrheal episodes following ED disposition, and the occurrence of palpitations, pre-syncope/syncope, chest pain, arrhythmias, and serious adverse events. For the secondary outcomes, the DOSE-AGE trial will investigate the individual elements of the Modified Vesikari Scale score and caregiver satisfaction with the therapy. DISCUSSION: The DOSE-AGE trial will provide evidence on the effectiveness of multiple doses of oral ondansetron, taken as needed, following an initial ED dose in children with acute gastroenteritis-associated vomiting. The data from the DOSE-AGE trial will be analyzed using this SAP. This will reduce the risk of producing data-driven results and bias in our reported outcomes. The DOSE-AGE study was registered on ClinicalTrials.gov on February 22, 2019. TRIAL REGISTRATION: ClinicalTrials.gov NCT03851835 . Registered on 22 February 2019.
引用
- Heath A, Rios JD, Williamson-Urquhart S, et al. A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan. Trials. 2020. PMID: 32838813. doi:10.1186/s13063-020-04651-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。